Resalis Therapeutics: Funding, Investors & Team (Sep 2026)
Resalis Therapeutics is focusing on addressing metabolic diseases by targeting a key regulator linked to obesity and fatty liver disease. The company is using its expertise in non-coding RNA drugs and lipid metabolism to develop a treatment called RES-010, which aims to provide effective weight loss and reduce liver fat. With promising preclinical results, Resalis plans to quickly move RES-010 into clinical trials for various metabolic disorders.
Resalis Therapeutics has raised $21.6M across 3 funding rounds on record, the most recent an undisclosed round announced in Oct 2024.
Resalis Therapeutics Company Profile and Key Stats
Latest funding round on record: Oct 2024.
Resalis Therapeutics Funding Rounds
1 of 3 rounds was announced without a disclosed amount and is excluded from the total.
Resalis Therapeutics raised $10.7M in a Seed announced in Feb 2023.
11 months later, a Series A of $10.9M was announced in Jan 2024.
9 months later, an undisclosed round was announced in Oct 2024 with no disclosed amount.
Resalis Therapeutics Founders and Leadership Team
Contact details for the Resalis Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Resalis Therapeutics Funding Compared to Other Biotechnology Startups
Funded Startups Like Resalis Therapeutics in Biotechnology and Torino
Companies Similar to Resalis Therapeutics
NOUS is a biotech startup working on developing a new era of ingredients for Food&Beverage and Nutraceutical…
Yeastime's value proposition is its innovative retrofitting ultrasound technology, which accelerates…
Oraigo is a leading company in the development of innovative road safety technology, utilizing brain-computer…
FTnet is a digital platform in the pharmaceutical industry that employs advanced technology to connect…
Genoa Instruments is a cutting-edge startup focused on revolutionizing biomedical and health research using…
CoRe is an Italian start-up, aimed at the study of new product and process solutions in the field of…
Established in 1999, PHSE is a leading provider of time-sensitive and temperature-controlled transport…
MOGU, an Italian-based European company, is dedicated to developing a variety of mycelium-based technologies…
A biotech business called DIAMANTE (Nano-Technologies for Autoimmune Disease) is dedicated to using plants to…
Relicta developed a water-soluble, transparent and biodegradable plastic for packaging made from fish…
Resalis Therapeutics Funding FAQs
What does Resalis Therapeutics do?
Resalis Therapeutics is focusing on addressing metabolic diseases by targeting a key regulator linked to obesity and fatty liver disease. The company is using its expertise in non-coding RNA drugs and lipid metabolism to develop a treatment called RES-010, which aims to provide effective weight loss and reduce liver fat. With promising preclinical results, Resalis plans to quickly move RES-010 into clinical trials for various metabolic disorders.
How much funding has Resalis Therapeutics raised?
Resalis Therapeutics has raised $21.6M across 3 rounds on record.
When did Resalis Therapeutics last raise funding?
Resalis Therapeutics' most recent funding round on record was announced in Oct 2024. The amount was not disclosed.
Who founded Resalis Therapeutics?
FundedIQ lists Riccardo Panella (Founder) at Resalis Therapeutics.
Where is Resalis Therapeutics headquartered?
Resalis Therapeutics is based in Torino, Piemonte, Italy.
How many employees does Resalis Therapeutics have?
Resalis Therapeutics is in the 1-10 employee band.
About FundedIQ's Resalis Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Resalis Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.